{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T05:38:50Z","timestamp":1787981930100,"version":"build-2784847793"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,12,18]],"date-time":"2019-12-18T00:00:00Z","timestamp":1576627200000},"content-version":"vor","delay-in-days":17,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Respir Res"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Macrolide is a key drug in the treatment of <jats:italic>Mycobacterium avium<\/jats:italic> complex pulmonary disease (MAC-PD). Macrolide-resistant MAC is gaining importance, but there are little data in clinical characteristics and treatment outcomes of macrolide-resistant MAC-PD (MR-MAC-PD).<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>We performed a systematic review and meta-analysis of published studies reporting clinical characteristics and treatment outcomes of patients with MR-MAC-PD. Risk of bias was assessed using the modified Newcastle-Ottawa Scale.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Nine studies (seven retrospective and two prospective) comprising 319 patients were identified through a database search. Around 73% were women, and 52% had the fibrocavitary form. Pooled sputum culture conversion rate after combined multiple antibiotics or surgical resection was 21% (95% confidence interval [CI], 14\u201330%), and the one-year all-cause mortality was 10% (95% CI, 5\u201320%). There was no significant difference in treatment outcomes between nodular bronchiectatic and fibrocavitary types.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>Even combination therapy with fluoroquinolone, aminoglycoside, and surgical resection, the treatment outcomes of MR-MAC-PD were poor. The investigation of new treatment modalities is urgent.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12931-019-1258-9","type":"journal-article","created":{"date-parts":[[2019,12,18]],"date-time":"2019-12-18T13:02:53Z","timestamp":1576674173000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["Clinical characteristics and treatment outcomes of patients with macrolide-resistant Mycobacterium avium complex pulmonary disease: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"20","author":[{"given":"Youngmok","family":"Park","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun Hye","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inkyung","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Goeun","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7783-5271","authenticated-orcid":false,"given":"Young Ae","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,12,18]]},"reference":[{"key":"1258_CR1","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1164\/rccm.200604-571ST","volume":"175","author":"DE Griffith","year":"2007","unstructured":"Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, Holland SM, Horsburgh R, Huitt G, Iademarco MF, et al. An official ATS\/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007;175:367\u2013416.","journal-title":"Am J Respir Crit Care Med"},{"key":"1258_CR2","doi-asserted-by":"publisher","first-page":"e000242","DOI":"10.1136\/bmjresp-2017-000242","volume":"4","author":"CS Haworth","year":"2017","unstructured":"Haworth CS, Banks J, Capstick T, Fisher AJ, Gorsuch T, Laurenson IF, Leitch A, Loebinger MR, Milburn HJ, Nightingale M, et al. British Thoracic Society guideline for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD). BMJ Open Respir Res. 2017;4:e000242.","journal-title":"BMJ Open Respir Res"},{"key":"1258_CR3","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.ccm.2014.10.002","volume":"36","author":"DR Prevots","year":"2015","unstructured":"Prevots DR, Marras TK. Epidemiology of human pulmonary infection with nontuberculous mycobacteria: a review. Clin Chest Med. 2015;36:13\u201334.","journal-title":"Clin Chest Med"},{"key":"1258_CR4","doi-asserted-by":"publisher","first-page":"15","DOI":"10.4046\/trd.2018.0060","volume":"82","author":"YS Kwon","year":"2019","unstructured":"Kwon YS, Koh WJ, Daley CL. Treatment of Mycobacterium avium complex pulmonary disease. Tuberc Respir Dis Seoul. 2019;82:15\u201326.","journal-title":"Tuberc Respir Dis Seoul"},{"key":"1258_CR5","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1164\/rccm.200603-450OC","volume":"174","author":"DE Griffith","year":"2006","unstructured":"Griffith DE, Brown-Elliott BA, Langsjoen B, Zhang Y, Pan X, Girard W, Nelson K, Caccitolo J, Alvarez J, Shepherd S, et al. Clinical and molecular analysis of macrolide resistance in Mycobacterium avium complex lung disease. Am J Respir Crit Care Med. 2006;174:928\u201334.","journal-title":"Am J Respir Crit Care Med"},{"key":"1258_CR6","doi-asserted-by":"publisher","first-page":"6758","DOI":"10.1128\/AAC.01240-16","volume":"60","author":"SM Moon","year":"2016","unstructured":"Moon SM, Park HY, Kim SY, Jhun BW, Lee H, Jeon K, Kim DH, Huh HJ, Ki CS, Lee NY, et al. Clinical characteristics, treatment outcomes, and resistance mutations associated with macrolide-resistant Mycobacterium avium complex lung disease. Antimicrob Agents Chemother. 2016;60:6758\u201365.","journal-title":"Antimicrob Agents Chemother"},{"key":"1258_CR7","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1513\/AnnalsATS.201604-246OC","volume":"13","author":"K Morimoto","year":"2016","unstructured":"Morimoto K, Namkoong H, Hasegawa N, Nakagawa T, Morino E, Shiraishi Y, Ogawa K, Izumi K, Takasaki J, Yoshiyama T, et al. Macrolide-resistant Mycobacterium avium complex lung disease: analysis of 102 consecutive cases. Ann Am Thorac Soc. 2016;13:1904\u201311.","journal-title":"Ann Am Thorac Soc"},{"key":"1258_CR8","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s12879-016-1384-7","volume":"16","author":"T Kadota","year":"2016","unstructured":"Kadota T, Matsui H, Hirose T, Suzuki J, Saito M, Akaba T, Kobayashi K, Akashi S, Kawashima M, Tamura A, et al. Analysis of drug treatment outcome in clarithromycin-resistant Mycobacterium avium complex lung disease. BMC Infect Dis. 2016;16:31.","journal-title":"BMC Infect Dis"},{"key":"1258_CR9","first-page":"e123","volume":"3","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Open Med. 2009;3:e123\u201330.","journal-title":"Open Med"},{"key":"1258_CR10","unstructured":"The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses [http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp]."},{"key":"1258_CR11","unstructured":"Rohatgi A: WebPlotDigitizer, v4.1. 2018."},{"key":"1258_CR12","unstructured":"Hedges L, Olkin, I.: Statistical methods for Meta-Analysis. 1st edn: Academic Press; 2014."},{"key":"1258_CR13","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1164\/ajrccm.160.3.9811086","volume":"160","author":"E Tanaka","year":"1999","unstructured":"Tanaka E, Kimoto T, Tsuyuguchi K, Watanabe I, Matsumoto H, Niimi A, Suzuki K, Murayama T, Amitani R, Kuze F. Effect of clarithromycin regimen for Mycobacterium avium complex pulmonary disease. Am J Respir Crit Care Med. 1999;160:866\u201372.","journal-title":"Am J Respir Crit Care Med"},{"key":"1258_CR14","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1186\/s12879-017-2665-5","volume":"17","author":"K Yagi","year":"2017","unstructured":"Yagi K, Ishii M, Namkoong H, Asami T, Iketani O, Asakura T, Suzuki S, Sugiura H, Yamada Y, Nishimura T, et al. The efficacy, safety, and feasibility of inhaled amikacin for the treatment of difficult-to-treat non-tuberculous mycobacterial lung diseases. BMC Infect Dis. 2017;17:558.","journal-title":"BMC Infect Dis"},{"key":"1258_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.rmed.2018.07.003","volume":"142","author":"ML Aznar","year":"2018","unstructured":"Aznar ML, Zubrinic M, Siemienowicz M, Hashimoto K, Brode SK, Mehrabi M, Patsios D, Keshavjee S, Marras TK. Adjuvant lung resection in the management of nontuberculous mycobacterial lung infection: a retrospective matched cohort study. Respir Med. 2018;142:1\u20136.","journal-title":"Respir Med"},{"key":"1258_CR16","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1164\/rccm.201807-1318OC","volume":"198","author":"DE Griffith","year":"2018","unstructured":"Griffith DE, Eagle G, Thomson R, Aksamit TR, Hasegawa N, Morimoto K, Addrizzo-Harris DJ, O'Donnell AE, Marras TK, Flume PA, et al. Amikacin liposome inhalation suspension for treatment-refractory lung disease caused by Mycobacterium avium complex CONVERT. A prospective, open-label, randomized study. Am J Respir Crit Care Med. 2018;198:1559\u201369.","journal-title":"Am J Respir Crit Care Med"},{"key":"1258_CR17","doi-asserted-by":"crossref","unstructured":"Asakura T, Suzuki S, Fukano H, Okamori S, Kusumoto T, Uwamino Y, Ogawa T, So M, Uno S, Namkoong H, et al. Sitafloxacin-containing regimen for the treatment of refractory mycobacterium avium complex lung disease. Open Forum Infectious Diseases. 2019;6.","DOI":"10.1093\/ofid\/ofz108"},{"key":"1258_CR18","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1093\/cid\/cix517","volume":"65","author":"N Kwak","year":"2017","unstructured":"Kwak N, Park J, Kim E, Lee CH, Han SK, Yim JJ. Treatment outcomes of Mycobacterium avium complex lung disease: a systematic review and meta-analysis. Clin Infect Dis. 2017;65:1077\u201384.","journal-title":"Clin Infect Dis"},{"key":"1258_CR19","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1016\/j.chest.2018.01.024","volume":"153","author":"R Diel","year":"2018","unstructured":"Diel R, Nienhaus A, Ringshausen FC, Richter E, Welte T, Rabe KF, Loddenkemper R. Microbiologic outcome of interventions against Mycobacterium avium complex pulmonary disease: a systematic review. Chest. 2018;153:888\u2013921.","journal-title":"Chest"},{"key":"1258_CR20","doi-asserted-by":"publisher","first-page":"i3","DOI":"10.1093\/jac\/dkx311","volume":"72","author":"JG Pasipanodya","year":"2017","unstructured":"Pasipanodya JG, Ogbonna D, Deshpande D, Srivastava S, Gumbo T. Meta-analyses and the evidence base for microbial outcomes in the treatment of pulmonary Mycobacterium avium-intracellulare complex disease. J Antimicrob Chemother. 2017;72:i3\u2013i19.","journal-title":"J Antimicrob Chemother"},{"key":"1258_CR21","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1093\/cid\/cix479","volume":"65","author":"SW Pan","year":"2017","unstructured":"Pan SW, Shu CC, Feng JY, Wang JY, Chan YJ, Yu CJ, Su WJ. Microbiological persistence in patients with Mycobacterium avium complex lung disease: the predictors and the impact on radiographic progression. Clin Infect Dis. 2017;65:927\u201334.","journal-title":"Clin Infect Dis"},{"key":"1258_CR22","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1186\/s12879-018-3113-x","volume":"18","author":"R Diel","year":"2018","unstructured":"Diel R, Lipman M, Hoefsloot W. High mortality in patients with Mycobacterium avium complex lung disease: a systematic review. BMC Infect Dis. 2018;18:206.","journal-title":"BMC Infect Dis"},{"key":"1258_CR23","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1164\/rccm.200905-0778OC","volume":"181","author":"C Andrejak","year":"2010","unstructured":"Andrejak C, Thomsen VO, Johansen IS, Riis A, Benfield TL, Duhaut P, Sorensen HT, Lescure FX, Thomsen RW. Nontuberculous pulmonary mycobacteriosis in Denmark: incidence and prognostic factors. Am J Respir Crit Care Med. 2010;181:514\u201321.","journal-title":"Am J Respir Crit Care Med"},{"key":"1258_CR24","doi-asserted-by":"publisher","first-page":"468","DOI":"10.3201\/eid2303.161927","volume":"23","author":"TK Marras","year":"2017","unstructured":"Marras TK, Campitelli MA, Lu H, Chung H, Brode SK, Marchand-Austin A, Winthrop KL, Gershon AS, Kwong JC, Jamieson FB. Pulmonary Nontuberculous mycobacteria-associated deaths, Ontario, Canada, 2001-2013. Emerg Infect Dis. 2017;23:468\u201376.","journal-title":"Emerg Infect Dis"},{"key":"1258_CR25","first-page":"1112","volume":"14","author":"SA Novosad","year":"2017","unstructured":"Novosad SA, Henkle E, Schafer S, Hedberg K, Ku J, Siegel SAR, Choi D, Slatore CG, Winthrop KL. Mortality after Respiratory Isolation of Nontuberculous Mycobacteria. A comparison of patients who did and did not meet disease criteria. Ann Am Thorac Soc. 2017;14:1112\u20139.","journal-title":"Ann Am Thorac Soc"},{"key":"1258_CR26","unstructured":"World Health Organization: Global tuberculosis report 2018 (WHO\/CDS\/TB\/2018.20). 2018."},{"key":"1258_CR27","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1164\/rccm.201206-1088OC","volume":"186","author":"WJ Koh","year":"2012","unstructured":"Koh WJ, Jeong BH, Jeon K, Lee SY, Shin SJ. Therapeutic drug monitoring in the treatment of Mycobacterium avium complex lung disease. Am J Respir Crit Care Med. 2012;186:797\u2013802.","journal-title":"Am J Respir Crit Care Med"},{"key":"1258_CR28","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1164\/rccm.201204-0682OC","volume":"186","author":"J van Ingen","year":"2012","unstructured":"van Ingen J, Egelund EF, Levin A, Totten SE, Boeree MJ, Mouton JW, Aarnoutse RE, Heifets LB, Peloquin CA, Daley CL. The pharmacokinetics and pharmacodynamics of pulmonary Mycobacterium avium complex disease treatment. Am J Respir Crit Care Med. 2012;186:559\u201365.","journal-title":"Am J Respir Crit Care Med"},{"key":"1258_CR29","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1378\/chest.14-2764","volume":"148","author":"JV Philley","year":"2015","unstructured":"Philley JV, Wallace RJ Jr, Benwill JL, Taskar V, Brown-Elliott BA, Thakkar F, Aksamit TR, Griffith DE. Preliminary results of Bedaquiline as salvage therapy for patients with Nontuberculous mycobacterial lung disease. Chest. 2015;148:499\u2013506.","journal-title":"Chest"},{"key":"1258_CR30","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1016\/j.chest.2017.04.175","volume":"152","author":"SL Martiniano","year":"2017","unstructured":"Martiniano SL, Wagner BD, Levin A, Nick JA, Sagel SD, Daley CL. Safety and effectiveness of Clofazimine for primary and refractory Nontuberculous mycobacterial infection. Chest. 2017;152:800\u20139.","journal-title":"Chest"}],"container-title":["Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-019-1258-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12931-019-1258-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-019-1258-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,17]],"date-time":"2020-12-17T00:43:54Z","timestamp":1608165834000},"score":1,"resource":{"primary":{"URL":"https:\/\/respiratory-research.biomedcentral.com\/articles\/10.1186\/s12931-019-1258-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1258"],"URL":"https:\/\/doi.org\/10.1186\/s12931-019-1258-9","relation":{},"ISSN":["1465-993X"],"issn-type":[{"value":"1465-993X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"26 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"286"}}